Apellis stock: buy or sell?
February 21st, 2020
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases.
Should I buy Apellis stock?Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. That's why is so important to define your own trading strategy that fits your character as inversor. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with Apellis stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Apellis Pharmaceuticals stock a buy?
Financial institutions and banks publish stock ratings everyday.Unfortunately, we couldn't detect any rating for APLS stock for the last 30 days.
Apellis stock analysis
Shares of Apellis plunged a spooky -5.32% and closed at $36.87.
Shares of Apellis Pharmaceuticals ended today at $36.87 and plunged a spooky -5.32%. On December APLS price bounced up over the SMA of 200 days demonstrating to be a significant support for this stock. Since last December when SMA50d and SMA100d crossed up, APLS price gained $9.60 per share (35.20%). On Feb/10, APLS hit new all time highs, pushing higher previous ATH of $44.47 recorded on Feb 4th. New ATHs are usual entry points for many trading setups as there aren't higher resistences.
Shares of Apellis closed this week at $36.87 and collapsed a chilling -12.17%. By mid January APLS boosted a cool 5.11% in just one week.
Apellis stock is drawing an uptrend with rising tops and bottoms. Now trading in between its last bottom and last top, APLS might consolidate in a flat-base, waiting to break out over or down under . Not so far away is the last all-time high Apellis marked last week, but since then it dropped a 18.14%. Since price and SMA40w lines crossed up early December, APLS climbed $12.88 (53.69%). Since SMA20d and SMA40w crossed up early May, APLS price climbed $17.29 per share (88.30%).
Apellis stock price history
Apellis IPO was on November 9th, 2017 at $14.50 per share1. Since then, APLS stock grew a 154.30%, with an average of 77.20% per year. If you had invested $1,000 in Apellis stock in 2017, it would worth $1,543.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Apellis stock historical price chart
APLS stock reached all-time highs on February 10th with a price of $45.04.
Apellis stock price targetNobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' APLS stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we have not detected any price prediction for Apellis Pharmaceuticals stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareApellis Pharmaceuticals let down analysts when it reported an Earnings per Share (EPS) of $-0.61 when the market consensus was $-0.65.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2011, last anual turnover report draw a fatal slide of -4.35% to $1,246.02 million dollars. When comparing 2012 vs 2011, however, profit margin (that is, the net income divided by revenues) plummed a -17.22% to 4.98%.
|2010||$936 M||-||$270 M28.8%||-|
|2011||$1,303 M||39.24%||$289 M22.2%||7.28%|
|2012||$1,246 M||-4.35%||$62 M5.0%||-78.54%|
Quarterly financial resultsReported quarter income marked $-36.46 M with a profit margin of . Profit margin stayed stable a 0.00% compared to previous quarter when profit margin was inf%. When comparing sales to same quarter last year, Apellis sales marked a neutral movement and stayed constant a nan%. Looking back to recent quarterly results, Apellis Pharmaceuticals posted 7 positive quarters in a row.
Apellis ownershipWhen you are planning to buy a stock, it's worth to check its ownership structure.
Apellis shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 22.31% of all shares.
In case of Apellis stock, 60.52% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for APLS stock account 0.00%, no big difference from last month.
For a better context understanding, the following table shows ownership data compared to other related companies:
|Market cap||$2.8 B|
|Total shares||74.9 M|
|Float shares||46.7 M|
|- Institutional holdings (%)||60.5%|
|- Insider holdings (%)||22.3%|
|Shares in short selling||0.0%|
|Friday, February 21st, 2020|
|Day range||$36.72 - $39.10|
|Average true range||$1.91|
|50d mov avg||$36.83|
|100d mov avg||$32.08|
|200d mov avg||$28.61|
Apellis performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. For Apellis Pharmaceuticals, the benchmark is made against .